BioNxt Solutions Inc. (CSE:BNXT)
Canada · Delayed Price · Currency is CAD 0.5000
+0.0500 (11.11%)
May 1, 2026, 10:22 AM EST
BioNxt Solutions Revenue
BioNxt Solutions had revenue of -11.26K CAD in the quarter ending December 31, 2025.
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
58.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| iAnthus Capital Holdings | 196.87M |
| Planet 13 Holdings | 141.74M |
| Decibel Cannabis Company | 112.72M |
| Vext Science | 66.63M |
| Rubicon Organics | 59.45M |
| Leef Brands | 47.70M |
| C21 Investments | 45.62M |
| MediPharm Labs | 45.12M |
BioNxt Solutions News
- 3 days ago - BioNxt Solutions Inc.: BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - Finanz Nachrichten
- 3 days ago - BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - Wallstreet:Online
- 3 days ago - BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - Accesswire
- 17 days ago - BioNxt Solutions Inc.: BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis - Finanz Nachrichten
- 17 days ago - BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS) - Accesswire
- 17 days ago - BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS) - Wallstreet:Online
- 24 days ago - BioNxt Solutions Inc.: BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries - Finanz Nachrichten
- 24 days ago - BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries - Accesswire